TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Chronic renal anemia~* Hemoglobin concentration in country-specific target range (Switzerland: 11 to 13 g/dL; Austria: 10 to 12 g/dL)~* Regular long-term hemodialysis therapy with the same mode of dialysis for ≥3 months~* Continuous intravenous or subcutaneous maintenance ESA treatment during previous 2 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Significant acute or chronic bleeding, such as overt gastrointestinal bleeding~* Active malignant disease (except non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera in Renal Anemia (Type: EXPERIMENTAL): Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients with first treatment cycle~* Age between 25 and 30 years,~* Infertility for at least 2 years' duration,~* Oligomenorrhea or amenorrhea associated with a positive Progesterone challenge test~* Women with normal concentrations of prolactin, free thyroxin and thyroid-stimulating hormone (TSH)~Exclusion Criteria:~* Women whose partners had an abnormal semen analysis according to World Health Organization~* Women who had uterine or tubal abnormalities on hysterosalpingography, and women who had a body mass index of \>30 kg/m2.

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- clomiphene citrate and ethinyl estradiol (Type: EXPERIMENTAL): Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
- clomiphene citrate and placebo (Type: ACTIVE_COMPARATOR): Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PreHospital Air Medical Plasma Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Hemorrhagic shock not responsive to crystalloid infusion -~Exclusion Criteria: Isolated Fall, Cervical cord injury, prisoner, pregnant patient, traumatic arrest~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- plasma (Type: EXPERIMENTAL): infusion of 2 units of plasma
- standard air medical care (Type: NO_INTERVENTION): control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 4 years old~* parasite count ≥ 1,000 asexual parasites/µL~* normal glucose-6-phosphate dehydrogenase enzyme level based on qualitative test (Trinity Biotech® no 203, USA)~* hemoglobin level ≥ 8 gr/dL as measured by Hemoque® apparatus;~* have the ability to return for 42-day-follow up and~* willingness to sign the informed-consent form.~Exclusion Criteria:~* are infected with other r plasmodium species~* have only gametocytes of P. falciparum;~* are pregnant - measured by positive result on HCG urine test and/or breastfeeding women~* present signs of pitting edema on both legs as a sign of malnutrition~* have complicated or severe malaria, other chronic diseases or history of drug allergies.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dihydroartemisinin-piperaquine (Type: ACTIVE_COMPARATOR): None
- Dihydroartemisininpiperaquine primaquine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Slow gait, defined by an over-ground preferred walking speed of less than or equal to 1.0 m/s.~* Executive dysfunction, defined by a Trail Making Test B z-score of greater than one standard deviation below age- and gender-based norms.~Exclusion Criteria:~* Non-ambulatory~* Clinical history or brain imaging evidence of a previous stroke~* Parkinson's Disease~* Normal pressure hydrocephalus~* Other neurodegenerative condition~* Severe depression~* Lower-extremity arthritis or pain causing slow gait~* Inability or unwillingness to understand or participate in the study protocol~* Contraindications to MRI or tDCS, including (but not limited to) personal or family history of epilepsy, use of neuro-active drugs, claustrophobia or risk of metal objects in the body.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Real tDCS (Type: EXPERIMENTAL): The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA.
- Sham tDCS (Type: SHAM_COMPARATOR): The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female individual 2-45 years of age~2. Participants/Parents who have voluntarily given informed consent and/or assent.~3. Participants/Parents willing to commit complying with the study procedures of the investigator and available for the entire duration of study~Exclusion Criteria:~1. Participants concomitantly enrolled or scheduled to be enrolled in another trial~2. Acute illness, in particular infectious diseases or fever (axillary temperature \> 38°C), with in three days prior to enrollment and vaccination.~3. Known history of allergy to vaccines or other medications~4. Known history of allergy to egg, chiken protein, neomycin and formaldehyde.~5. History of uncontrolled coagulopathy or blood disorders~6. Known history of immune function disorders including immunodeficiency diseases, or chronic use of systemic steroids (\> 20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs~7. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the trial objectives~8. Pregnancy \& Lactation (female adults)~9. Female with child-bearing potential during the study period. i.e., sexually active and not practicing effective acceptable contraceptive method~10. Individuals who have previously received any vaccines against typhoid fever~11. Individuals already immunized with any licensed vaccine within 4 weeks prior to enrolment/vaccination (day 0) and expected to receive other licensed vaccines within 60 days following the first dose (day 0), except for tetanus toxoid vaccine~12. Individuals who have a previously ascertained or suspected disease caused by S. typhi.~13. Individuals who have had household contact with/and or intimate exposure to an individual with laboratory-confirmed S. typhi~14. History of alcohol or substance abuse~15. Subject planning to move from the study area before the end of study period

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Test group (Type: EXPERIMENTAL): Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
- Comparator group (Type: ACTIVE_COMPARATOR): Biological/Vaccine:~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. At least 60 years of age and diagnosis of previously untreated AML (either de novo or from an antecedent hematologic disorder or therapy related AML)~2. At least 20% blasts by BM biopsy or aspirate~3. ECOG performance status of 0,1,or 2~4. Adequate cardiac, renal and liver function~Key Exclusion Criteria:~1. Uncontrolled DIC~2. Active central nervous system involvement by AML~3. Requiring hemodialysis or peritoneal dialysis~4. Some prior history of heart attack or stroke (depending on how long ago the event occurred)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Study Patients (Type: EXPERIMENTAL): * Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~* Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~* Schedule C: 72 mg/m2 on Days 1 and 4, or~* Schedule C: 90 mg/m2 on Days 1 and 4

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Low Level Laser Light Therapy on Circumference Reduction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) between 25 kg/m² and 40 kg/m²~* Subject indicated for liposuction or use of liposuction techniques for the removal of localized deposits of adipose tissues that do not respond to diet and exercise for the hips, waist, thighs and upper abdomen. (As per the American Academy of Cosmetic Surgery's 2006 Guidelines for Liposuction Surgery developed by A joint Ad Hoc Committee of the American Society of Lipo-Suction Surgery (ASLSS) and the American Academy of Cosmetic Surgery (AACS))~* Willing and able to abstain from treatments other than the study procedure for body contouring/circumference reduction/weight loss during study participation~* Willing and able to maintain typical diet and exercise regimen during study participation~Exclusion Criteria:~* Body Mass Index (BMI) less than 25 kg/m² or greater than 40 kg/m²~* Known cardiovascular disease~* Cardiac surgeries such as bypass, heart transplant surgery, pacemakers~* Prior surgical intervention for body sculpting/weight loss~* Medical, physical, or other contraindications for body sculpting/weight loss~* Current use of medication known to affect weight levels/cause bloating or swelling and for which abstinence during study participation is not possible~* Any medical condition known to affect weight levels and/or cause bloating or swelling.~* Diagnosis of, and/or taking medication for, irritable bowel syndrome.~* Active infection, wound or other external trauma to the study treatment areas~* Known photosensitivity disorder~* Active cancer or currently receiving treatment for cancer~* Pregnant or planning pregnancy prior to study participation end~* Serious mental health illness such as dementia/schizophrenia; psychiatric hospitalization in past two years.~* Developmental disability or cognitive impairment that may preclude adequate comprehension of the consent form and/or ability to record the study measures~* Involvement in litigation/worker's compensation/disability benefits related to the study parameters~* Participation in clinical research in the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Erchonia EZ6 Laser (Type: EXPERIMENTAL): The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Misoprostol for Fetal Demise

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: healthy hemodynamically stable females with a non-viable pregnancy~-~Exclusion Criteria:~* orthostatic hypotension, contraindication to either mifepristone or misoprostol, treatment during current pregnancy to provide surgical or medical evacuation of the uterus, evidence of ovarian hyperstimulation syndrome, known or suspected pelvic infection,known or suspected clotting defect or receiving anticoagulants, cardiovascular disease, current breastfeeding, pregnancy with and IUD in situ, current participation in another clinical trial, prior participation in this trial, suspected or confirmed endometrial AV malformation, clinical indication requiring the karyotyping of products of conception

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \< 75 years~* Type-2 diabetes~* Therapy resistant hypertension (by ABPM)~* Treatment with at least 3 antihypertensives~Exclusion Criteria:~* HbA1c \> 10.0~* BP \> 180/110 mmHg~* Secondary hypertension~* Intolerance to spironolactone~* Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids~* Total cholesterol 10 mmol/l~* New York Heart Association class III and IV~* Pregnancy or planned pregnancy~* Psychiatric disease~* Malignant disease~* Insufficient adherence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- addition of spironolactone (Type: EXPERIMENTAL): spironolactone is added to previous antihypertensive treatment
- Placebo (Type: PLACEBO_COMPARATOR): Addition of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of S-ketamine in Cesarean Section Combined Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA status I-III~* Age 20 to 45~* 37-42 weeks gestation~* undergo elective cesarean section with subarachnoid anesthesia~* participate in this study and sign informed consent~Exclusion Criteria:~* Patients with contraindications for cesarean section~* Patients with contraindications of combined spinal and epidural anesthesia~* Patients with severe systemic disease~* Alcoholism and long-term use of anti-inflammatory and analgesic drugs~* Patients who were unable to cooperate or refused to participate in the trial~* Patients with contraindications to esketamine and hydromorphone

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group E1 (Type: EXPERIMENTAL): S-ketamine was administered intravenously after delivery，patient controlled epidural analgesia（PCEA）was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
- Group E2 (Type: EXPERIMENTAL): S-ketamine was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA) was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml
- Group C1 (Type: PLACEBO_COMPARATOR): placebo was administered intravenously after delivery，patient controlled epidural analgesia（PCEA) was administered postoperatively PCEA formula：（10μg/ml hydromorphone+0.11% ropivacaine) 200ml
- Group C2 (Type: PLACEBO_COMPARATOR): placebo was administered intravenously after delivery，patient controlled intravenous analgesia（PCIA） was administered postoperatively PCIA formula：（100μg/ml hydromorphone) 100ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented clinical diagnosis of Major Depressive Disorder.~* Be able to understand and comply with the requirements of the study.~* Able to understand and provide written informed consent~Exclusion Criteria:~* Patients (female) must not be pregnant or lactating~* Current or past diagnosis of stroke or transient ischemic attack (TIA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes~* Patients with HbA1c ≥7.5% and ≤10.5% and who are on a stable insulin regimen of at least 30 IU of injectable insulin per day either without any other oral antidiabetic drug or with a stable dose of oral antidiabetic drugs~Exclusion Criteria:~* Type 1 Diabetes~* Treatment with more than two additional oral antidiabetic drugs~* Moderate and severe renal (kidney) failure or dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 2.5mg
- 2 (Type: EXPERIMENTAL): 5mg
- 3 (Type: EXPERIMENTAL): 10mg
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete